Literature DB >> 11921277

APC/CTNNB1 (beta-catenin) pathway alterations in human prostate cancers.

Amy V Gerstein1, Teresa Acosta Almeida, Guojing Zhao, Eric Chess, Ie-Ming Shih, Kent Buhler, Kenneth Pienta, Mark A Rubin, Robert Vessella, Nickolas Papadopoulos.   

Abstract

Genetic alterations serve as beacons for the involvement of specific pathways in tumorigenesis. It was previously shown that 5% of prostate tumors harbor CTNNB1 mutations, suggesting that this tumor type may involve a deregulated APC/CTNNB1 pathway. To explore this possibility further, we searched for mutations in genes implicated in this pathway in 22 samples that included cell lines, xenografts, and primary tumors. We identified seven alterations: two in CTNNB1, three in APC, and two in hTRCP1 (also known as BTRC) which controls the degradation of CTNNB1. Alterations in the CTNNB1 regulatory domain, APC, and hTRCP1 were mutually exclusive, consistent with their equivalent effects on CTNNB1 stability. These results suggest that CTNNB1 signaling plays a critical role in the development of a significant fraction of prostate cancers. Moreover, they provide the first evidence that hTRCP1 plays a role in human neoplasia. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11921277     DOI: 10.1002/gcc.10037

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  47 in total

1.  A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303.

Authors:  Federico Innocenti; Kouros Owzar; Nancy L Cox; Patrick Evans; Michiaki Kubo; Hitoshi Zembutsu; Chen Jiang; Donna Hollis; Taisei Mushiroda; Liang Li; Paula Friedman; Liewei Wang; Dylan Glubb; Herbert Hurwitz; Kathleen M Giacomini; Howard L McLeod; Richard M Goldberg; Richard L Schilsky; Hedy L Kindler; Yusuke Nakamura; Mark J Ratain
Journal:  Clin Cancer Res       Date:  2011-12-05       Impact factor: 12.531

2.  Protocadherin-PC promotes androgen-independent prostate cancer cell growth.

Authors:  Stephane Terry; Luis Queires; Sixtina Gil-Diez-de-Medina; Min-Wei Chen; Alexandre de la Taille; Yves Allory; Phuong-Lan Tran; Claude C Abbou; Ralph Buttyan; Francis Vacherot
Journal:  Prostate       Date:  2006-07-01       Impact factor: 4.104

3.  Activation of β-catenin signaling in androgen receptor-negative prostate cancer cells.

Authors:  Xinhai Wan; Jie Liu; Jing-Fang Lu; Vassiliki Tzelepi; Jun Yang; Michael W Starbuck; Lixia Diao; Jing Wang; Eleni Efstathiou; Elba S Vazquez; Patricia Troncoso; Sankar N Maity; Nora M Navone
Journal:  Clin Cancer Res       Date:  2012-02-01       Impact factor: 12.531

4.  Cytogenetically balanced translocations are associated with focal copy number alterations.

Authors:  Spencer K Watson; Ronald J deLeeuw; Doug E Horsman; Jeremy A Squire; Wan L Lam
Journal:  Hum Genet       Date:  2006-10-19       Impact factor: 4.132

Review 5.  Regulation of cancer stem cells by RING finger ubiquitin ligases.

Authors:  Bin Kang; Xiao-Hong Sun
Journal:  Stem Cell Investig       Date:  2014-02-09

6.  The beta-catenin binding protein ICAT modulates androgen receptor activity.

Authors:  Ming Zhuo; Chunfang Zhu; JingLucy Sun; William I Weis; Zijie Sun
Journal:  Mol Endocrinol       Date:  2011-09-01

7.  Identification of a novel role of ZMIZ2 protein in regulating the activity of the Wnt/β-catenin signaling pathway.

Authors:  Suk Hyung Lee; Chunfang Zhu; Yue Peng; Daniel T Johnson; Lynn Lehmann; Zijie Sun
Journal:  J Biol Chem       Date:  2013-10-30       Impact factor: 5.157

8.  Sox7 Is an independent checkpoint for beta-catenin function in prostate and colon epithelial cells.

Authors:  Lizheng Guo; Diansheng Zhong; Stephen Lau; Xiuju Liu; Xue-Yuan Dong; Xiaodong Sun; Vincent W Yang; Paula M Vertino; Carlos S Moreno; Vijay Varma; Jin-Tang Dong; Wei Zhou
Journal:  Mol Cancer Res       Date:  2008-09       Impact factor: 5.852

9.  No association between a candidate TCF7L2 variant and risk of breast or ovarian cancer.

Authors:  Ellen L Goode; Csilla Szabo; Ludmila Prokunina-Olsson; Robert A Vierkant; Zachary S Fredericksen; Francis S Collins; Kristin L White; Michele Schmidt; Brooke L Fridley; Fergus J Couch
Journal:  BMC Cancer       Date:  2009-09-04       Impact factor: 4.430

10.  Axin downregulates TCF-4 transcription via beta-catenin, but not p53, and inhibits the proliferation and invasion of lung cancer cells.

Authors:  Lian-He Yang; Hong-Tao Xu; Yang Han; Qing-Chang Li; Yang Liu; Yue Zhao; Zhi-Qiang Yang; Qian-Ze Dong; Yuan Miao; Shun-Dong Dai; En-Hua Wang
Journal:  Mol Cancer       Date:  2010-02-02       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.